@article {Ito502, author = {Hiromu Ito and Shigeyoshi Tsuji and Masanori Nakayama and Yuichi Mochida and Keiichiro Nishida and Hajime Ishikawa and Toshihisa Kojima and Takumi Matsumoto and Ayako Kubota and Takeshi Mochizuki and Koji Sakuraba and Isao Matsushita and Arata Nakajima and Ryota Hara and Akihisa Haraguchi and Tsukasa Matsubara and Katsuaki Kanbe and Natsuko Nakagawa and Masahide Hamaguchi and Shigeki Momohara and the JOSRA Consortium}, editor = {Ito, Hiromu and Tsuji, Shigeyoshi and Nakayama, Masanori and Mochida, Yuichi and Nishida, Keiichiro and Ishikawa, Hajime and Kojima, Toshihisa and Matsumoto, Takumi and Kubota, Ayako and Mochizuki, Takeshi and Sakuraba, Koji and Matsushita, Isao and Nakajima, Arata and Hara, Ryota and Haraguchi, Akihisa and Matsubara, Tsukasa and Kanbe, Katsuaki and Nakagawa, Natsuko and Momohara, Shigeki and Tanaka, Sakae and Miyahara, Hisaaki and Tanaka, Yasuhito and Hashimoto, Jun and Nakashima, Yasuharu and Kaneko, Atsushi and Matsuda, Shuichi}, title = {Does Abatacept Increase Postoperative Adverse Events in Rheumatoid Arthritis Compared with Conventional Synthetic Disease-modifying Drugs?}, volume = {47}, number = {4}, pages = {502--509}, year = {2020}, doi = {10.3899/jrheum.181100}, publisher = {The Journal of Rheumatology}, abstract = {Objective. To investigate whether abatacept (ABA) causes more adverse events (AE) than conventional synthetic disease-modifying antirheumatic drugs (csDMARD) after orthopedic surgery in patients with rheumatoid arthritis (RA).Methods. A retrospective multicenter nested case{\textendash}control study was performed in 18 institutions. Patients receiving ABA (ABA group) were matched individually with patients receiving csDMARD and/or steroids (control group). Postoperative AE included surgical site infection, delayed wound healing, deep vein thrombosis or pulmonary embolism, flare, and death. The incidence rates of the AE in both groups were compared with the Mantel-Haenszel test. Risk factors for AE were analyzed by logistic regression model.Results. A total of 3358 cases were collected. After inclusion and exclusion, 2651 patients were selected for matching, and 194 patients in 97 pairs were chosen for subsequent comparative analyses between the ABA and control groups. No between-group differences were detected in the incidence rates of each AE or in the incidence rates of total AE (control vs ABA: 15.5\% vs 20.7\% in total, 5.2\% vs 3.1\% in death).Conclusion. Compared with csDMARD and/or steroids without ABA, adding ABA to the treatment does not appear to increase the incidence rates of postoperative AE in patients with RA undergoing orthopedic surgery. Large cohort studies should be performed to add evidence for the perioperative safety profile of ABA.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/47/4/502}, eprint = {https://www.jrheum.org/content/47/4/502.full.pdf}, journal = {The Journal of Rheumatology} }